32nd week of 2013 patent applcation highlights part 49 |
Patent application number | Title | Published |
20130203728 | PYRROLIDINE COMPOUNDS - The present application relates to compounds of formula | 2013-08-08 |
20130203729 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS - The present invention relates to compounds of formula (I): | 2013-08-08 |
20130203730 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS - A compound of formula I | 2013-08-08 |
20130203731 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS - The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formula | 2013-08-08 |
20130203732 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE - Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2013-08-08 |
20130203733 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES - The present invention is based, in part, on assays we conducted that revealed compounds that may be used to treat or prevent diseases characterized by an abnormal or undesirable association of one protein with another. | 2013-08-08 |
20130203734 | ANTI-INFLAMMATORY AGENTS - Disclosed herein are methods of preventing or treating inflammatory diseases using sulfonamide analogs of 3-aminolactam compounds, each with aromatic “tail groups”. Compounds as defined by formulae (I) and (I′), and the medical uses of the compounds, are described herein. | 2013-08-08 |
20130203735 | CAPROLACTAM MGLUR5 RECEPTOR MODULATORS - The present invention is directed to caprolactams which are positive allosteric modulators of metabotropic glutamate receptors, particularly the mGluR5 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved. | 2013-08-08 |
20130203736 | AGONIST/ANTAGONIST COMPOSITIONS AND METHODS OF USE - The present invention relates to novel compositions comprising an agonist and an antagonist, in certain ratios which allow for the onset of agonist action followed quickly by alleviation by antagonist action, and methods of use in personal defense and law enforcement. | 2013-08-08 |
20130203737 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS - The present invention relates to a fused heterocyclic derivative of the formula (I) | 2013-08-08 |
20130203738 | USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) - The present invention identifies a compound which binds to the PAH1 domain of mSin3B that specifically binds to neural restrictive silencer factor NRSF, and uses the compound as a prophylactic and/or a therapeutic for diseases associated with abnormal expression of neural restrictive silencer factor NRSF/REST or abnormal expression of genes targeted by NRSF/REST, such as Huntington's disease, medulloblastoma and neuropathic pain. | 2013-08-08 |
20130203739 | CYCLIC AMIDE DERIVATIVE | 2013-08-08 |
20130203740 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES - The present invention relates to a fused aminodihydrothiazine derivative of formula (I): | 2013-08-08 |
20130203741 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES - A compound represented by the general formula: | 2013-08-08 |
20130203742 | VALACICLOVIR AND MELOXICAM COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valaciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of valaciclovir and meloxicam. | 2013-08-08 |
20130203743 | FAMCICLOVIR AND MELOXICAM COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound famciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of famciclovir and meloxicam. | 2013-08-08 |
20130203744 | ACICLOVIR AND MELOXICAM COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound aciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of aciclovir and meloxicam. | 2013-08-08 |
20130203745 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS - The present invention relates to bisaryl(thio)morpholine derivatives of the formula (I) | 2013-08-08 |
20130203746 | TETRACYCLIC COMPOUNDS - This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2013-08-08 |
20130203747 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION - Compounds of formula I: | 2013-08-08 |
20130203748 | Inhibitors of Human Immunodeficiency Virus Replication - The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. | 2013-08-08 |
20130203749 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy - The present invention relates to tetrahydroisoquinoline of the formula (I) | 2013-08-08 |
20130203750 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS - The present invention provides a pyrrolidine compound of General Formula (1) | 2013-08-08 |
20130203751 | SUBSTITUTED 8-ALKOXY-2-AMINOTETRALIN DERIVATIVES, AND USE THEREOF - The present application relates to novel substituted 8-alkoxy-2-aminotetraline derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders. | 2013-08-08 |
20130203752 | PHENYLMORPHOLINES AND ANALOGUES THEREOF - Provided herein are compounds and prodrugs and methods of preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or more monoamine neurotransmitters, including dopamine, serotonin, and norepinephrine. Also provided are pharmaceutical compositions comprising one or more of these compounds or prodrugs, which may further comprise one or more additional therapeutic agents. Also provided are methods of treatment of various conditions that may be responsive to modification of monoamine neutrotransmitter levels, such as pre-obesity, obesity, addiction, and depression. | 2013-08-08 |
20130203753 | MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE - Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed. | 2013-08-08 |
20130203754 | 2-Aryl Imidazo[1,2-a]Pyridine-3-Acetamide Derivatives, Preparation Methods and Uses Thereof - Disclosed are 2-arylimidazo[1,2- | 2013-08-08 |
20130203755 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE - Provided are compounds having an inhibitory effect on kinases including Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders that comprise the inhibition of Mixed Lineage Kinases. | 2013-08-08 |
20130203756 | ISOINDOLINE PDE10 INHIBITORS - The present invention is directed to isoindolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. | 2013-08-08 |
20130203757 | Compounds And Compositions For Treating Cancer - The invention relates to compounds and composition for the treatment and prevention of cancer. The invention also covers all diseases that may be treated by selective modulation of levels of reactive oxygen species in diseased cells versus normal cells. Methods for the preparation and administration of such compositions are also disclosed. | 2013-08-08 |
20130203758 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2013-08-08 |
20130203759 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT - Disclosed are compressed tablets containing atazanavir sulfate and an acidifying agent, optionally with another active agent, e.g., anti-HIV agents, and optionally with precipitation retardant agents. Also disclosed are processes for making the tablets, and methods of treating HIV. | 2013-08-08 |
20130203760 | Polymorphs of Brimonidine Pamoate - A brimonidine pamoate polymorph exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system. | 2013-08-08 |
20130203761 | Polymorphs of Brimonidine Pamoate - A brimonidine pamoate polymorph exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system. | 2013-08-08 |
20130203762 | VETERINARY ANTIPROLACTINIC COMPOSITION FOR RUMINANTS - This present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition comprises at least one antiprolactinic compound which is an agonist of dopamine receptors, and is particularly useful for reducing udder engorgement and/or the reduction of pain after drying off and/or of increasing welfare, and/or of reducing milk leakage in ruminants as well as for preventing new mammary microbial infections, secondary infection, or co-infections in ruminants and mastitis. | 2013-08-08 |
20130203763 | SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS - The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against c-Met and are useful in treating disorders related to abnormal protein kinase activities such as cancer. | 2013-08-08 |
20130203764 | TREATMENT OF CANCER/INHIBITION OF METASTASIS - Substances and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. Inhibition of metastatic cell behaviours such as detachability, lateral motility, transverse migration and invasiveness is demonstrated using the known drugs ranolazine and riluzole. | 2013-08-08 |
20130203765 | DEUTERATED PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 - The invention is directed to novel deuterated pyrrolopyrimidine compounds of formula (I) wherein R | 2013-08-08 |
20130203767 | Treatment of Pulmonary Hypertension - This invention relates to the use of certain cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension. | 2013-08-08 |
20130203768 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES - This invention relates to certain N-heteroaryl compounds that are generally useful as medicaments, more specifically as medicaments for animals. The medicament can preferably be used for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to the preparation of the N-heteroaryl compounds. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds. | 2013-08-08 |
20130203769 | Targeting Metabolic Adaptive Responses to Chemotherapy - Methods for targeting adaptive responses to chemotherapy are described. In various embodiments, a method comprises administering at least one compound that inhibits S6K1, mTORC, or upstream or downstream pathway components of S6K1 or mTORC, in association with administration of at least one antagonist of PPARα, PPARδ, or PGC1α. In various embodiments, the compound that inhibits S6K1, mTORC, or upstream or downstream pathway components of S6K1 or mTORC is rapamycin, everolimus, temsirolimus, or imatinib. The antagonist of PPARα, PPARδ, or PGC1α can be GW7647, GW6471, GW501516, GSK3787, or GSK0660. | 2013-08-08 |
20130203770 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS - There are provided bicyclic carbonylamino-pyrazoles of formula (I), wherein the variables are as specified in the claims, for use as medicament, in particular for the treatment of diseases due to the malfunctioning of protein kinases (PKs), such as cancer, pharmaceutical compositions comprising such carbamoyl derivatives, and their use as prodrugs of therapeutically active agents. Method of treatment and some new bicyclic carbonylamino-pyrazoles are also object of the present invention. | 2013-08-08 |
20130203771 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM - A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. | 2013-08-08 |
20130203772 | Polymorphs and Salts - The present invention is directed to a polymorph of a compound and salts of a compound and polymorphs thereof, which compound is an inhibitor of kinase activity. | 2013-08-08 |
20130203773 | Pharmaceutical dosage form for immediate release of an indolinone derivative - The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate. | 2013-08-08 |
20130203774 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF - The present invention relates to compounds of the general formula (I) wherein R | 2013-08-08 |
20130203775 | Novel Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2013-08-08 |
20130203776 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS - Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R | 2013-08-08 |
20130203777 | Identification of Stabilizers of Multimeric Proteins - Disclosed herein are compounds and compositions thereof which find use in increasing stability of TTR tetramers reducing its tendency to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of TTR and therby decreasing aggegate formation by TTR. Also disclosed herein are methods to screen for candidate compounds that increase stability of TTR. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein. | 2013-08-08 |
20130203778 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRIMIDINEONE DERIVATIVE - The present patent application relates to a pharmaceutical composition comprising a fused pyrimidineone derivative having transient receptor potential modulating activity and a hydrophilic carrier. | 2013-08-08 |
20130203779 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 2013-08-08 |
20130203780 | FAMCICLOVIR AND DICLOFENAC COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound famciclovir and a therapeutically-effective amount of the COX-2 inhibitor diclofenac. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of famciclovir and diclofenac. | 2013-08-08 |
20130203781 | ACICLOVIR AND CELECOXIB COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound aciclovir and a therapeutically-effective amount of the COX-2 inhibitor celecoxib. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of aciclovir and celecoxib. | 2013-08-08 |
20130203782 | ACICLOVIR AND DICLOFENAC COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound aciclovir and a therapeutically-effective amount of the COX-2 inhibitor diclofenac. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of aciclovir and diclofenac. | 2013-08-08 |
20130203783 | VALACICLOVIR AND CELECOXIB COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valaciclovir and a therapeutically-effective amount of the COX-2 inhibitor celecoxib. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of valaciclovir and celecoxib. | 2013-08-08 |
20130203784 | VALACICLOVIR AND DICLOFENAC COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valaciclovir and a therapeutically-effective amount of the COX-2 inhibitor diclofenac. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of valaciclovir and diclofenac. | 2013-08-08 |
20130203785 | Valomaciclovir Polymorphs - The present invention relates to crystalline forms of valomaciclovir, processes for preparing crystalline forms of valomaciclovir, pharmaceutical compositions thereof and methods of using thereof. | 2013-08-08 |
20130203786 | SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES - The present invention is directed to novel amino-substituted seven-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 2013-08-08 |
20130203787 | HYDRATE OF 1--5,5-DIFLUORO-PIPERIDIN-2-ONE TARTRATE - The present invention relates to 1.5 hydrate of of 1-{(2S)-2-amino-4-[2,4-bis (trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-di-fluoropiperidin-2-one tartrate, a process for preparing the same, and a pharmaceutical composition for inhibiting DPP-IV, which comprises said compound as the active component. | 2013-08-08 |
20130203788 | EGFR AND KRAS MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and KRAS and methods of detecting such mutations as well as prognostic methods for identifying tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein and/or a mutated KRAS gene or mutated KRAS protein in a tumor sample. | 2013-08-08 |
20130203789 | Novel Inhibitors of LYN Kinase and Methods Using Same - The invention includes compounds that inhibit LYN kinase activity. The invention further includes a method of treating, ameliorating or preventing cancer in a subject in need thereof, wherein the cancer is dependent on LYN kinase activity. | 2013-08-08 |
20130203790 | SULFUR-CONTAINING COMPOUNDS AS ANTI-PROLIFERATIVE AGENTS - Novel sulphur-containing compounds and pharmaceutically acceptable salts thereof are disclosed, which have utility as anti-proliferative agents against mammalian cells. The invention provides a method for synthesizing the sulphur-containing compounds. | 2013-08-08 |
20130203791 | Tablets and Preparation Thereof - The present invention features processes of making tablets having reduced internal fractures. In one aspect, the processes comprise the steps of (1) compressing a pre-tabletting material in a die to form a tablet, where an internal surface of the die is lubricated with at least one lubricant, and the pre-tabletting material comprises at least one therapeutic agent and at least one pharmaceutically acceptable polymer; and (2) ejecting said tablet from said die. In another aspect, the processes employ a granular or powdery pre-tabletting material which comprises at least one therapeutic agent and at least one pharmaceutically acceptable polymer, wherein 90% of the particles in the pre-tabletting material are smaller than 400 μm. | 2013-08-08 |
20130203792 | CO-CRYSTALS OF PYRIMETHANIL OR CYPRODINIL - The present invention relates to co-crystals of cyprodinil or pyrimethanil and a co-crystal forming compound which has at least one imide and/or oxime functional group. | 2013-08-08 |
20130203793 | Protection and Treatment Against Influenza Infection - Method and composition for protection and treatment against influenza viral infection by modulating the activity of at least one essential host signaling pathways, including the Hedgehog (Hh), the Bone Morphogenetic Protein (BMP), the Notch (N) signaling pathways or combinations thereof, which activity is altered by the viral protein NS1. The method and composition comprise use of a compound that modulates at least one of these essential host signaling pathways for preventing or controlling symptoms associated with influenza viral infection. The method or composition can also be used either alone or in combination with other therapeutic agents for treating or protecting against influenza infection, and associated syndromes. | 2013-08-08 |
20130203794 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER - The present invention relates to compounds for modulating sonic hedgehog signaling and preventing or treating cancer. | 2013-08-08 |
20130203795 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) - The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects. | 2013-08-08 |
20130203796 | INJECTABLE FLOWABLE COMPOSITION COMPRISING BUPRENORPHINE - The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis. | 2013-08-08 |
20130203797 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR BILIARY DISEASES - A therapeutic or prophylactic agent for biliary tract diseases includes as an effective component a specific compound having a morphinan skeleton represented by Compound 1, or a pharmaceutically acceptable acid addition salt thereof: | 2013-08-08 |
20130203798 | DIAGNOSIS AND TREATMENT OF FUNCTIONAL DYSPEPSIA AND IRRITABLE BOWEL SYNDROME - Methods for diagnosing, monitoring, and treating functional dyspepsia and/or irritable bowel syndrome, are disclosed comprising determining the presence of enterovirus in a gastrointestinal biopsy, wherein the presence of enterovirus indicates disease. | 2013-08-08 |
20130203799 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS - Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors. | 2013-08-08 |
20130203800 | METHOD FOR DETECTING NON-TRANSFERRIN BOUND IRON - A method of quantifying non-transferrin bound iron (NTBI) in a biological fluid is provided, the method comprising: | 2013-08-08 |
20130203801 | TREATMENT OF ADDICTION - The invention discloses methods for preventing or treating addiction by administering to a subject in need thereof a PARP inhibitor. | 2013-08-08 |
20130203802 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS - A compound of Formula (I) or a pharmaceutically acceptable salt thereof: | 2013-08-08 |
20130203803 | Azaindazole Amide Compounds As CCR1 Receptor Antagonists - Disclosed are CCR1 inhibitor compounds of the formula (I): which are useful in the treatment of autoimmune and other diseases. Also disclosed a pharmaceutical compositions containing the same, and methods of making and using same. | 2013-08-08 |
20130203804 | SOLIFENACIN SALTS - The invention concerns fumarate salts of solifenacin, as well as pharmaceutical compositions comprising fumarate salts of solifenacin. The invention furthermore concerns a process for preparing solifenacin and salts thereof. The fumarate salt provides improved properties over the known solifenacin salts, especially in terms of its stability. The novel process for its preparation is furthermore improved over known processes for preparing solifenacin in that it provides a higher yield and recovers a greater amount of starting material. | 2013-08-08 |
20130203805 | Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase - The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds. | 2013-08-08 |
20130203806 | CILOSTAZOL COCRYSTALS AND COMPOSITIONS - The invention relates to improvements of the physiochemical and/or the pharmaceutical properties of cilostazol. Disclosed herein are several new compositions and cocrystals of cilostazol, including: a 1:1 cilostazol gentisic acid cocrystal, a 1:1:1 cilostazol gentisic acid H | 2013-08-08 |
20130203807 | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNF THERAPY - This application provides for a method of treating a human patient afflicted with anti-TNFα refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day. | 2013-08-08 |
20130203808 | Drug for degradation and treatment of biofilms - The invention comprising decoquinate and one or both of a redox drug or macrolide drug for prophylaxis or treatment of certain biofilms and plaques in humans and animals. | 2013-08-08 |
20130203809 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS - The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof. | 2013-08-08 |
20130203810 | Identification, Assessment, and Therapy of Cancers with Innate or Acquired Resistance to ALK Inhibitors - Described herein are compositions, kits, and methods for determining whether subjects having cancer(s) positive for ALK mutations are likely to respond to treatment with an ALK inhibitor and/or whether a patient having such cancer(s) is likely to have a relatively slower disease progression. Further described are methods for prognosing a time course of disease in a subject having such cancer. | 2013-08-08 |
20130203811 | THALIDOMIDE AND THALIDOMIDE ANALOGUES FOR THE PREVENTION AND TREATMENT OF SARCOPENIA - The present invention relates to thalidomide and/or thalidomide analogues and methods for using same to maintain or increase muscle mass to prevent and/or treat sarcopenia. The invention also provides pharmaceutical compositions comprising thalidomide and thalidomide analogues for the prevention and/or treatment of sarcopenia. | 2013-08-08 |
20130203812 | IONIC SILICONE HYDROGELS COMPRISING PHARMACEUTICAL AND/OR NUTRICEUTICAL COMPONENTS AND HAVING IMPROVED HYDROLYTIC STABILITY - The present invention relates to ionic silicone hydrogel polymers displaying improved thermal stability. More specifically, the present invention relates to a polymer formed from reactive components comprising at least one silicone component and at least one ionic component comprising at least one anionic group. The polymers of the present invention display good thermal stability and desirable protein uptake. | 2013-08-08 |
20130203813 | MEDICAL DEVICES HAVING HOMOGENEOUS CHARGE DENSITY AND METHODS FOR MAKING SAME - The present invention relates to ionic silicone hydrogel polymers comprising at least one pharmaceutical or nutriceutical component and displaying improved lysozyme uptake, low contact angle and reduced water soluble polymeric ammonium salt uptake. | 2013-08-08 |
20130203814 | Association of Rare Recurrent Genetic Variations to Attention-Deficit, Hyperactivity Disorder (ADHD) and Methods of Use Thereof for the Diagnosis and Treatment of the Same - Compositions and methods for the detection and treatment of ADHD are provided. | 2013-08-08 |
20130203815 | CYTOKINE INHIBITORS - The present invention provides compounds represented by general formula (I): | 2013-08-08 |
20130203816 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE - The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. | 2013-08-08 |
20130203817 | Novel Inhibitors of LYN Kinase - The invention includes novel compounds that inhibit LYN kinase activity. The invention further includes a method of treating, ameliorating or preventing cancer in a subject in need thereof, wherein the cancer is dependent on LYN kinase activity. | 2013-08-08 |
20130203818 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. | 2013-08-08 |
20130203819 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 2013-08-08 |
20130203820 | Thiazolidinedione analogues - The present invention relates to thiazolidinedione analogues that are useful for treating metabolic inflammation mediated diseases such as diabetes. | 2013-08-08 |
20130203821 | Pyridine Compounds for Controlling Invertebrate Pests II - The present invention relates to novel pyridine compounds of the formulae I and II, to their salts, to their tautomers, to their N-oxides, and to the salts of these N-oxides or tautomers. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests. The invention also relates to a method for controlling in-vertebrate pests by using these compounds. The invention further relates to plant propagation material and to agricultural compositions comprising said compounds. | 2013-08-08 |
20130203822 | COMPOUNDS FOR TREATMENT OF TUMORS BEARING DEREGULATED MYC ONCOPROTEINS - Compound of Formula (I): wherein R | 2013-08-08 |
20130203823 | STABLE TOPICAL COMPOSITIONS FOR 1,2,4-THIADIAZOLE DERIVATIVES - The present application provides a stable topical composition comprising a compound of 1,2,4-thiadiazole derivatives and the related thiourea derivatives. The stable topical composition may be present in various forms, including aqueous gel, cream, and emulsion. The stable topical composition may be stored at refrigerated or ambient condition for a reasonable shelf-life. The present application also provides a method of treating dermatologic disorders mediated by a melanocortin receptor using the stable topical composition. The stable composition may be delivered using a single chamber or dual chamber device. A method of preparing and delivering the stable composition is also provided. | 2013-08-08 |
20130203824 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The invention relates to compounds of structural formula (I): | 2013-08-08 |
20130203825 | PHOSPHATE-FREE HIGHLY CONCENTRATED AQUEOUS DISPERSION COMPOSITION OF BIOCIDES AND PROCESS FOR PREPARING THE SAME - A phosphate-free, highly-concentrated aqueous dispersion composition comprising at least one biocide, sulfosuccinate based surfactant, block copolymer, suspending agent, and optionally an antifoaming agent and desired additives if any. The composition of the present application is significantly stable against heat, cold, transit, storage and dilution for at least 18 months. The preferred biocides of the dispersion composition are 2-meth-4-isothiazolin-3-one (MIT), 1,2-Benzisothiazolin-3-one (BIT), 5-Chloro-2-methyl-4-isothiazolin-3-one (CMIT), 2-Octyl-4-isothiazolin-3-one (Off) 3-Iodo-2-propynylbutyl carbamate (IPBC), oxyfluorfen, thiabendazole, terbutryn, zinc pyrithione (ZnPy), bronopol, folpet, diiiron, dehydroacetic acid (DHA), dazomet and carbendazim alone or in combination. Also disclosed is a process for preparing the dispersion composition and appropriate applications thereof. | 2013-08-08 |
20130203826 | Pure Intermediate - The present invention relates to an improved process for the preparation of Letrozole (I) and its synthetic intermediate 4-[(1-(1,2,4-triazoly)methyl]benzonitrile (III). In particular, it relates to a process to prepare Letrozole and its intermediate (III) substantially free from regioisomeric impurities. The present invention further relates to acid addition salts of 4-[(1-(1,2,4-triazoly)methyl]benzonitrile (III) such as the oxalate salt, and also to Letrozole (I), the intermediate (III) and salts thereof preparable by the processes of the present invention. | 2013-08-08 |
20130203827 | POLYMORPHISMS IN THE PDE3A GENE - Embodiments of the invention are directed to identifying or treating a patient that would benefit from phosphodiesterase inhibitor therapy. | 2013-08-08 |
20130203828 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES - The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection. | 2013-08-08 |